Marker Therapeutics, Inc. – NASDAQ:MRKR
Marker Therapeutics stock price today
$1.13
-2.36
-67.62%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 4 hours
Marker Therapeutics stock price monthly change
-33.27%
month
Marker Therapeutics stock price quarterly change
-33.27%
quarter
Marker Therapeutics stock price yearly change
-17.69%
year
Marker Therapeutics key metrics
Market Cap | 30.59M |
Enterprise value | N/A |
P/E | -0.25 |
EV/Sales | -0.07 |
EV/EBITDA | 0.01 |
Price/Sales | 1.33 |
Price/Book | 0.20 |
PEG ratio | N/A |
EPS | -1.63 |
Revenue | 3.32M |
EBITDA | -12.82M |
Income | -5.59M |
Revenue Q/Q | -64.45% |
Revenue Y/Y | -75.02% |
Profit margin | -648.35% |
Oper. margin | -645.64% |
Gross margin | 0.3% |
EBIT margin | -645.64% |
EBITDA margin | -386.07% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMarker Therapeutics stock price history
Marker Therapeutics stock forecast
Marker Therapeutics financial statements
| Jun 2023 | 762.65K | 2.51M | 329.87% |
|---|---|---|---|
| Sep 2023 | 257.60K | -2.98M | -1157.57% |
| Dec 2023 | 1.05M | -2.74M | -259.35% |
| Mar 2024 | 1.24M | -2.39M | -192.34% |
| 2027 | 37.97M | -5.54M | -14.62% |
|---|
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 21955648 | 2.92M | 13.3% |
|---|---|---|---|
| Sep 2023 | 19486567 | 2.77M | 14.26% |
| Dec 2023 | 17127391 | 3.07M | 17.95% |
| Mar 2024 | 14091899 | 2.30M | 16.35% |
| Jun 2023 | -7.05M | 18.77M | 736 |
|---|---|---|---|
| Sep 2023 | -1.12M | 18.66M | 479.27K |
| Dec 2023 | -2.36M | -18.66M | 5.13K |
| Mar 2024 | -3.83M | 0 | 49.09K |
Marker Therapeutics alternative data
| Aug 2023 | 67 |
|---|---|
| Sep 2023 | 67 |
| Oct 2023 | 67 |
| Nov 2023 | 67 |
| Dec 2023 | 67 |
| Jan 2024 | 67 |
| Feb 2024 | 67 |
| Mar 2024 | 67 |
| Apr 2024 | 67 |
| May 2024 | 8 |
| Jun 2024 | 8 |
| Jul 2024 | 8 |
Marker Therapeutics other data
60.78%
+37.39%
of MRKR is owned by hedge funds
18
-26
507.57K
-1.44M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2024 | 554250 | 0 |
| Quarter | Transcript |
|---|---|
| Q1 2021 12 May 2021 | Q1 2021 Earnings Call Transcript |
| Q1 2020 12 May 2020 | Q1 2020 Earnings Call Transcript |
| Q3 2019 13 Nov 2019 | Q3 2019 Earnings Call Transcript |
| Q4 2017 6 Apr 2018 | Q4 2017 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Peter L. Hoang MBA (1972) Pres, Chief Executive Officer & Director | $625,880 |
| Mr. Anthony H. Kim (1976) Chief Financial Officer | $550,910 |
| Dr. Mythili Koneru M.D., Ph.D. (1978) Chief Medical Officer | $538,600 |
-
What's the price of Marker Therapeutics stock today?
One share of Marker Therapeutics stock can currently be purchased for approximately $1.13.
-
When is Marker Therapeutics's next earnings date?
Unfortunately, Marker Therapeutics's (MRKR) next earnings date is currently unknown.
-
Does Marker Therapeutics pay dividends?
No, Marker Therapeutics does not pay dividends.
-
How much money does Marker Therapeutics make?
Marker Therapeutics has a market capitalization of 30.59M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 63.23% to 3.31M US dollars.
-
What is Marker Therapeutics's stock symbol?
Marker Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "MRKR".
-
What is Marker Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Marker Therapeutics?
Shares of Marker Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Marker Therapeutics's key executives?
Marker Therapeutics's management team includes the following people:
- Mr. Peter L. Hoang MBA Pres, Chief Executive Officer & Director(age: 53, pay: $625,880)
- Mr. Anthony H. Kim Chief Financial Officer(age: 49, pay: $550,910)
- Dr. Mythili Koneru M.D., Ph.D. Chief Medical Officer(age: 47, pay: $538,600)
-
How many employees does Marker Therapeutics have?
As Jul 2024, Marker Therapeutics employs 8 workers, which is 88% less then previous quarter.
-
When Marker Therapeutics went public?
Marker Therapeutics, Inc. is publicly traded company for more then 23 years since IPO on 16 Jul 2002.
-
What is Marker Therapeutics's official website?
The official website for Marker Therapeutics is markertherapeutics.com.
-
Where are Marker Therapeutics's headquarters?
Marker Therapeutics is headquartered at 3200 Southwest Freeway, Houston, TX.
-
How can i contact Marker Therapeutics?
Marker Therapeutics's mailing address is 3200 Southwest Freeway, Houston, TX and company can be reached via phone at +7 134006400.
Marker Therapeutics company profile:
Marker Therapeutics, Inc.
markertherapeutics.comExchange:
NASDAQ
Full time employees:
8
Industry:
Biotechnology
Sector:
Healthcare
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
3200 Southwest Freeway
Houston, TX 77027
Houston, TX 77027
CIK: 0001094038
ISIN: US57055L2060
CUSIP: 57055L107
